Loading
Life sciences · Journal article
Discover Oncology · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Exosomal non-coding RNAs (ncRNAs) are recognized as functionally active molecules that mediate communication between the tumor microenvironment (TME) and cancer stem cells (CSCs). While individual studies have reported this crosstalk, an integrated overview of how TME-derived exosomal ncRNAs versus tumor-derived exosomal ncRNAs co-ordinately drive CSC metabolic and epigenetic plasticity to sustain stemness and therapy resistance is warranted. This review critically explores recent evidences regarding how exosomal ncRNAs released by the tumor or TME-stromal components, like cancer-associated fibroblasts, macrophages and mesenchymal stem cells, rewire CSC metabolic plasticity under different stress conditions. These exosomal ncRNAs can direct specific adaptations in CSCs that help them escape cell death and co-evolve with the TME. Additionally, emerging links between environmental or lifestyle exposures and CSC regulation via exosomal ncRNAs, an area that remains obscure yet highly relevant to cancer prevention and treatment, has been divulged. Beyond mechanistic insights, the opportunities and challenges of exploiting exosomal ncRNAs as non-invasive biomarkers and therapeutic targets has also been delineated. Current research may thereby advance the development of exosomal ncRNAs as ultra-sensitive liquid biomarkers for predicting CSC-mediated disease relapse and design therapeutic strategies to eliminate the drug resistant populations in patients to ensure good patient prognosis.